Thompson Davis & CO. Inc. lifted its stake in Co-Diagnostics, Inc. (NASDAQ:CODX – Free Report) by 37.8% in the fourth quarter, Holdings Channel.com reports. The firm owned 57,200 shares of the company’s stock after buying an additional 15,700 shares during the period. Thompson Davis & CO. Inc.’s holdings in Co-Diagnostics were worth $43,000 at the end of the most recent quarter.
Separately, Jane Street Group LLC purchased a new position in shares of Co-Diagnostics in the 3rd quarter worth approximately $55,000. 14.99% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright reiterated a “neutral” rating and issued a $1.50 target price on shares of Co-Diagnostics in a report on Monday, November 11th.
Co-Diagnostics Stock Performance
Shares of Co-Diagnostics stock opened at $0.71 on Friday. The stock has a market cap of $22.51 million, a price-to-earnings ratio of -0.51 and a beta of -0.63. The stock has a 50 day moving average price of $0.75 and a 200-day moving average price of $1.04. Co-Diagnostics, Inc. has a one year low of $0.65 and a one year high of $2.23.
Co-Diagnostics Profile
Co-Diagnostics, Inc, a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting.
See Also
- Five stocks we like better than Co-Diagnostics
- How to Use the MarketBeat Stock Screener
- 3 Stocks Poised to Thrive as NVIDIA Dominates the AI Boom
- Utilities Stocks Explained – How and Why to Invest in Utilities
- MercadoLibre: High-Growth EM Stock With 100% Upside Potential
- How to Invest in the Best Canadian Stocks
- As the Magnificent 7 Stalls, These 3 Stocks Are Gaining Momentum
Want to see what other hedge funds are holding CODX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Co-Diagnostics, Inc. (NASDAQ:CODX – Free Report).
Receive News & Ratings for Co-Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Co-Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
